{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:24Z","timestamp":1791521424306,"version":"4.3.4"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The subcutaneous histrelin acetate implant is FDA-approved for 12 months of continuous gonadotropin-releasing hormone (GnRH) agonist therapy in central precocious puberty (CPP). Published data demonstrated sustained suppression with a single implant for up to approximately 24 months; however, efficacy beyond this duration has not been reported. A 7 years 5 month old female patient presented with bilateral Tanner 2 breast development, a bone age of 10 years, and laboratory findings consistent with early central activation. Treatment was delayed 11 months due to disruptions in care during the COVID-19 pandemic, and a histrelin implant was placed at age 8 years 5 months. The patient was lost to follow-up and returned at nearly 14 years of age, approximately 68 months after the implant placement, with primary amenorrhea and pubertal arrest. Laboratory evaluation before implant removal showed suppressed but detectable gonadotropins with a prepubertal estradiol, consistent with sustained partial suppression of the hypothalamic-pituitary-gonadal (HPG) axis sufficient to arrest pubertal progression. Her predicted adult height (PAH) of 167.6\u00a0cm (66 inches) approximated her mid-parental height (MPH) of 166.4\u00a0cm (65.5 inches). This case demonstrates that a single histrelin acetate implant may maintain clinically meaningful pubertal suppression for at least 68 months. These findings support broader investigations into the pharmacokinetics of extended implant use, given implications for reducing surgical burden and healthcare costs in CPP management.<\/jats:p>","DOI":"10.3389\/fendo.2026.1951374","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:19Z","timestamp":1791519979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Sustained pubertal suppression for 68 months with a single histrelin acetate implant in central precocious puberty"],"prefix":"10.3389","volume":"17","author":[{"given":"Sofya","family":"Ilmer","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology and Metabolism, Northwell Health","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Salemi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology and Metabolism, Northwell Health","place":["New Hyde Park, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1024","article-title":"Treatment and outcomes of precocious puberty: an update","volume":"98","author":"Fuqua","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(23)00237-7","article-title":"Central precocious puberty: a review of diagnosis, treatment, and outcomes","volume":"7","author":"Zevin","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcp0800459","article-title":"Precocious puberty","volume":"358","author":"Carel","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2022-0557","article-title":"Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty","volume":"36","author":"Ray","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00213","article-title":"Precocious puberty or premature thelarche: analysis of a large patient series in a single tertiary center with special emphasis on 6- to 8-year-old girls","volume":"8","author":"Varimo","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag168","article-title":"Central precocious puberty: an Endocrine Society clinical practice guideline","volume":"111","author":"Latronico","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14578","article-title":"Interpretation of reproductive hormones before, during and after the pubertal transition\u2014identifying health and disordered puberty","volume":"95","author":"Howard","year":"2021","journal-title":"Clin Endocrinol"},{"key":"B8","volume-title":"SUPPRELIN LA- histrelin acetate implant Drug Label","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3031","article-title":"Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial","volume":"100","author":"Silverman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10370.x","article-title":"Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer","volume":"109","author":"Shore","year":"2012","journal-title":"BJU Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67816-0","article-title":"An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer","volume":"163","author":"Chertin","year":"2000","journal-title":"J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14410","article-title":"Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis","volume":"94","author":"Luo","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2021-0114","article-title":"Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years","volume":"34","author":"Vargas Trujillo","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/eje-15-0590","article-title":"Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty","volume":"174","author":"Guaraldi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1216","article-title":"Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function","volume":"93","author":"Pasquino","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000513702","article-title":"Fertility of women treated during childhood with triptorelin (depot formulation) for central precocious puberty: the PREFER study","volume":"93","author":"Martinerie","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1515\/jpem-2023-0480","article-title":"The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis","volume":"37","author":"Guo","year":"2024","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1951374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:20Z","timestamp":1791519980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1951374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":17,"alternative-id":["10.3389\/fendo.2026.1951374"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1951374","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1951374"}}